Tumor Markers in Chronic Renal Failure and Hemodialysis Patients

Cases, Aleix; Filella, Xavier; Molina, Rafael; Ballesta, Antonio M.; López-Pedret, J; Revert, L

doi:10.1159/000186247

Cited by 75 publications

(59 citation statements)

References 10 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with benign lung, gastrointestinal and urological diseases had slightly higher BR Monitor levels. Particularly, renal insufficiency is known to potentially cause elevated levels (24,25). In this group, single values reached more than 100 kU/L.…”

Section: Discussionmentioning

confidence: 73%

Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® BR Monitor assay on the UniCel® DxI 800 Immunoassay System

Molina¹,

Gion²,

Gressner³

et al. 2008

Clinical Chemistry and Laboratory Medicine

Self Cite

View full text Add to dashboard Cite

Background: Cancer antigen CA15-3 antigen is known as a valuable marker for the management of breast cancer. Methods:The analytical and clinical performance of the Access ᮋ BR Monitor Immunoassay System (Beckman Coulter) was evaluated at five different European sites and compared with a reference system, defined as CA15-3 on the Elecsys ᮋ System (Roche Diagnostics). Results: Total imprecision (%CV) of the BR Monitor ranged between 5.5% and 11.7%, and inter-laboratory reproducibility between 3.4% and 5.1%. Linearity upon dilution showed a mean recovery of 98.5% (SD"9.1%). Endogenous interferents had no influence on BR Monitor levels (mean recoveries: hemoglobin 112%, bilirubin 111%, triglycerides 108%). There was no high-dose hook effect up to 13,540 kU/L. Clinical performance investigated in sera from 1811 individuals showed a general correlation between the Access BR Monitor and Elecsys CA15-3 (Rs0.797), with a slope of 1.383. CA15-3 serum levels, as measured by the BR Monitor, were low in healthy individuals (ns267, medians11.9 kU/L, 95th percentiles23.5 kU/L), higher in individuals with various benign diseases (ns549, medianss11.3-15.6 kU/L, 95th percentiless21.6-54.6 kU/L) and even higher in

show abstract

Section: Discussionmentioning

confidence: 73%

Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® BR Monitor assay on the UniCel® DxI 800 Immunoassay System

Molina¹,

Gion²,

Gressner³

et al. 2008

Clinical Chemistry and Laboratory Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…In contrast, higher c-erbB-2 sensitivity was found in both early diagnosis and at diagnosis of recurrence in ER-or PR-tumours. When using a parameter as a diagnostic tool, specificity is more important than sensitivity. C-erbB-2, CEA and CA 15.3 are not specific tumour markers and several benign diseases are associated with abnormal levels of these markers (Colomer et al, 1989;Cases et al, 1991;Molina et al, 1995Molina et al, , 1996. Six (5.3%) NED patients had elevated c-erbB-2, three (3.2%) had elevated CEA and two (2.1%) had elevated CA 15.3 when the classical cut-offs of 15 Uml-1 (c-erbB-2), 5 ng ml-' (CEA) and 35 U ml-' (CA 15.3) were used.…”

Section: Discussionmentioning

confidence: 99%

Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3

Molina

Jo²,

Zanón³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

Summary To evaluate the utility of c-erbB-2, carcinoembryonic antigen (CEA) and CA 15.3 in the early diagnosis of recurrence, serial serum determinations of these antigens were performed in 200 patients (followup 1-4 years, mean 2.2 years) with primary breast cancer and no evidence of residual disease (NED) after radical treatment (radical mastectomy or simple mastectomy and radiotherapy). Eighty-nine patients developed metastases during follow-up. C-erbB-2, CEA and CA 15.3 were elevated (>20 U ml -, > 0 ng ml-or >60 U ml-1 respectively) before diagnosis in 28%, 30% and 47% of the 89 patients with recurrence, with a lead time of 4.5 + 2.4, 4.9+2.4 and 4.8 + 2.4 months respectively. Tumour marker sensitivity was clearly related to the site of recurrence, with the lowest sensitivity found in locoregional relapse and the highest in patients with liver metastases. When patients with locoregional recurrences were excluded, sensitivity improved: 31 % (cerbB-2), 33% (CEA) and 56% (CA 15.3), with 76% having at least one of the three tumour markers. C-erbB-2 sensitivity in early diagnosis was significantly higher in patients with c-erbB-2 overexpression in tissue (8/10, 80%) than in those without overexpression (1/30, 3.3%) (P=0.0001). Likewise, higher levels of both, c-erbB-2 and CA 15.3 at diagnosis of recurrence, higher sensitivity in early diagnosis of relapse and a higher lead time were found in PR+ patients (CA 15.3, P<0.0001) or in PR-patients (c-erbB-2, P=0.009). Specificity of the tumour markers was 100% for all three markers (111 NED patients). In conclusion, c-erbB-2 is a useful tool for early diagnosis of metastases, mainly in those patients with c-erbB-2 overexpression in tissue. Using all three markers simultaneously it is possible to increase the sensitivity in the early diagnosis of recurrence by 11.2%.

show abstract

“…Although it is known that almost all "tumour markers" can be elevated in non-malignant disease (1)(2)(3)(4)(13)(14)(15), it remains unclear from the literature as to the role of renal insufficiency and the post renaltransplant period in the elevation of tumour markers, which are not purely renally excreted.…”

Section: Discussionmentioning

confidence: 99%

“…It was seen howin-vitro tests suitable for the early detection of cancer, ever, that the same tumour associated antigens were the lack of diagnostic sensitivity and specificity has expressed and released in non-malignant states, thus* prevented such methods being used for screening pur-preventing their use for screening purposes (3). poses.…”

mentioning

confidence: 99%

Anomalous Tumour Marker Concentrations in Renal Transplant Patients

Wood¹,

Steinhoff²,

Kessler³

1993

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Summary: Serial serum determinations of the tumour associated antigens carcinoembryonic antigen, tissue polypeptide antigen, CA 19-9, CA 15-3 and CA 125 were performed on 70 patients who were undergoing, or had undergone renal transplantation.The period of observation ranged from 4 days pre-operative to 708 days post-operative, although daily monitoring was usually carried out during the first 14-35 days post-operatively.With the exception of tissue polypeptide antigen, which was analysed with an immunoluminometric assay, all analytes were measured with the Enzymun-Test® System ES-300 using immunoenzymometric assays with colorimetric determination. The interassay coefficients of variation were less than 5% for the immunoenzymometric assays and 8.7% for tissue polypeptide antigen, all values being derived from 20 consecutive assays.Only 8/70 patients with no complications showed normal concentrations for all five analytes. 6/79 patients showed parallel changes of at least three markers. 7/70 patients had transient elevations of at least one marker, whereas 25/70 patients had a continual elevation of CA 125, 9/70 CA 19-9 and 1/70 CA 15-3, although no patient showed evidence of disease. Two patients, each with 2 rejection episodes, showed daily fluctuations up to 100% for all markers, with the exception of carcinoembryonic antigen. There was no correlation between elevated tumour markers and cytomegalovirus infection.° uc on leased into the circulation, thus allowing an early and Despite the vast amount of research on developing specific detection of malignancies. It was seen howin-vitro tests suitable for the early detection of cancer, ever, that the same tumour associated antigens were the lack of diagnostic sensitivity and specificity has expressed and released in non-malignant states,

show abstract

Tumor Markers in Chronic Renal Failure and Hemodialysis Patients

Cited by 75 publications

References 10 publications

Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® BR Monitor assay on the UniCel® DxI 800 Immunoassay System

Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® BR Monitor assay on the UniCel® DxI 800 Immunoassay System

Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3

Anomalous Tumour Marker Concentrations in Renal Transplant Patients

Contact Info

Product

Resources

About